This year’s most-read articles on CKD highlighted research and insights on drug approvals, guidelines, and value-based care.

Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated ...

The ustekinumab (Stelara; Janssen Biotech) biosimilar DMB-3115 (Imuldosa; Accord BioPharma) demonstrated clinical efficacy and safety comparable to the reference product through 52 weeks in a recent ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

Previously, the FDA required that RWE submissions include private, confidential information at the individual patient level. This requirement made it impractical to use many large databases containing ...

The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...

Multivariable analyses confirmed that vaccination remained associated with lower hospitalization risk in both periods after controlling for comorbid conditions. Compared with vaccinated patients, the ...

Chronic kidney disease (CKD) is a well-established risk factor for cardiovascular (CV) disease because declining kidney ...

Chronic kidney disease (CKD) significantly amplifies cardiovascular (CV) risk, with CV disease remaining the leading cause of ...

The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

The report is based on the experience of a patient with recurrent retroperitoneal DDLPS and is believed to be the first reported case in which such a patient achieved a pathological complete response ...